Pfizer Eliminates Roadblock To Remicade Biosimilar Launch

October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.

More from Biosimilars

More from Biosimilars & Generics